CN102355907A - 用苯达莫司汀和抗cd20抗体的组合治疗癌症 - Google Patents

用苯达莫司汀和抗cd20抗体的组合治疗癌症 Download PDF

Info

Publication number
CN102355907A
CN102355907A CN2010800123232A CN201080012323A CN102355907A CN 102355907 A CN102355907 A CN 102355907A CN 2010800123232 A CN2010800123232 A CN 2010800123232A CN 201080012323 A CN201080012323 A CN 201080012323A CN 102355907 A CN102355907 A CN 102355907A
Authority
CN
China
Prior art keywords
bendamustine
antibody
antibodies
described method
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800123232A
Other languages
English (en)
Chinese (zh)
Inventor
C.T.托马斯
G.钱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN102355907A publication Critical patent/CN102355907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800123232A 2009-01-16 2010-01-15 用苯达莫司汀和抗cd20抗体的组合治疗癌症 Pending CN102355907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14521009P 2009-01-16 2009-01-16
US61/145,210 2009-01-16
PCT/US2010/021123 WO2010083365A1 (en) 2009-01-16 2010-01-15 Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody

Publications (1)

Publication Number Publication Date
CN102355907A true CN102355907A (zh) 2012-02-15

Family

ID=42340093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800123232A Pending CN102355907A (zh) 2009-01-16 2010-01-15 用苯达莫司汀和抗cd20抗体的组合治疗癌症

Country Status (13)

Country Link
US (1) US20110274697A1 (enExample)
EP (1) EP2405937A4 (enExample)
JP (1) JP2012515217A (enExample)
KR (1) KR20110111303A (enExample)
CN (1) CN102355907A (enExample)
AU (1) AU2010204666A1 (enExample)
BR (1) BRPI1006829A2 (enExample)
CA (1) CA2749151A1 (enExample)
EA (1) EA201170940A1 (enExample)
IL (1) IL213794A0 (enExample)
MX (1) MX2011007589A (enExample)
SG (1) SG172792A1 (enExample)
WO (1) WO2010083365A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121338A (zh) * 2016-07-13 2019-08-13 武田药品工业株式会社 脾酪氨酸激酶抑制剂和其他治疗剂的组合
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
CN110540593A (zh) * 2018-05-29 2019-12-06 无锡智康弘义生物科技有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263798A1 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating prostate cancer
WO2024263804A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263801A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263813A3 (en) * 2023-06-21 2025-04-10 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating colorectal cancer

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3866783A4 (en) 2018-10-16 2022-08-03 US Nano Food & Drug Inc INTRATUMOR INJECTION FORMULATION
KR20220167271A (ko) 2020-04-13 2022-12-20 유에스 나노 푸드 앤 드럭 인코포레이티드 염기성 화학요법 종양내 주사 제형
US20230279138A1 (en) 2020-07-27 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Novel bispecific anti-cd3/cd20 polypeptide complex formulation
GB202218493D0 (en) * 2022-12-08 2023-01-25 Oncopeptides Ab Novel therapeutic combinations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089885A1 (en) * 2006-10-10 2008-04-17 Vaccinex, Inc. Anti-cd20 antibodies and methods of use
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744275T3 (es) * 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US20080089885A1 (en) * 2006-10-10 2008-04-17 Vaccinex, Inc. Anti-cd20 antibodies and methods of use

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121338A (zh) * 2016-07-13 2019-08-13 武田药品工业株式会社 脾酪氨酸激酶抑制剂和其他治疗剂的组合
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
CN110540593A (zh) * 2018-05-29 2019-12-06 无锡智康弘义生物科技有限公司 新型的抗cd3/抗cd20双特异性抗体
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263798A1 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating prostate cancer
WO2024263804A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263801A3 (en) * 2023-06-20 2025-03-27 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263813A3 (en) * 2023-06-21 2025-04-10 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating colorectal cancer

Also Published As

Publication number Publication date
WO2010083365A1 (en) 2010-07-22
KR20110111303A (ko) 2011-10-10
JP2012515217A (ja) 2012-07-05
EA201170940A1 (ru) 2012-02-28
CA2749151A1 (en) 2010-07-22
MX2011007589A (es) 2011-08-17
EP2405937A1 (en) 2012-01-18
IL213794A0 (en) 2011-07-31
SG172792A1 (en) 2011-08-29
BRPI1006829A2 (pt) 2016-10-25
EP2405937A4 (en) 2012-06-20
US20110274697A1 (en) 2011-11-10
AU2010204666A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
CN102355907A (zh) 用苯达莫司汀和抗cd20抗体的组合治疗癌症
JP6313825B2 (ja) 癌の治療のための抗−４−１ｂｂ抗体及びａｄｃｃ誘導抗体の組合せ
KR102158467B1 (ko) Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
KR101278395B1 (ko) 항-ｂｃｌ-2 활성제와 유형 ⅱ 항-ｃｄ20 항체의 조합 요법
US20100111945A1 (en) Novel uses
US20160090421A1 (en) Novel Uses
KR20220097932A (ko) 항-pvrig 항체 제제 및 항-pd-1 항체를 사용한 병용 요법
JP2012521379A (ja) アフコシル化抗体と、ヒトｇｍ−ｃｓｆ、ヒトｍ−ｃｓｆ及び／又はヒトｉｌ−３から選択される１又は２以上のサイトカインとの組合せ療法
US12195547B2 (en) Dosing for combination treatment with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate
TW201808333A (zh) 使用奧法木單抗（ofatumumab）治療多發性硬化症之療程及方法
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CN118103399A (zh) 喹啉衍生物与抗cd47抗体的药物组合
EP4410836A1 (en) Anti-cd47 antibody for combined treatment of blood tumor
CN120678937A (zh) 抗nkg2a抗体联合用药的新用途
HK40045394A (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2012121958A2 (en) Combination
HK1212996B (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120215